Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published: April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like Generative AI creates life-saving antibiotics from scratch September 2, 2025 Randomized trial demonstrates enhanced stent expansion in severely calcified coronary nodules November 2, 2026 Understanding the varied impact of COVID-19 in Shanghai and Hong Kong: A comparative analysis February 15, 2024
Randomized trial demonstrates enhanced stent expansion in severely calcified coronary nodules November 2, 2026
Understanding the varied impact of COVID-19 in Shanghai and Hong Kong: A comparative analysis February 15, 2024